• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOSPHERE MEDICAL, S.A. EMBOSPHERE MICROSPHERES; AGENTS, EMBOLIC, TREAT. UTER. FIBRO

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOSPHERE MEDICAL, S.A. EMBOSPHERE MICROSPHERES; AGENTS, EMBOLIC, TREAT. UTER. FIBRO Back to Search Results
Catalog Number S220GH
Device Problem Migration or Expulsion of Device (1395)
Patient Problem Pain (1994)
Event Date 06/10/2014
Event Type  Injury  
Event Description
It has been reported that a patient with hepatocellular carcinoma (stage iii) developed an acute pancreatitis immediately after trans arterial embolisation (tae) performed near to the gastroduodenal artery with the device (embosphere microspheres).On the same day, the patient was placed on nil per os status in consideration of the risk of ischemic pancreatitis developing as a complication, since a small amount of embosphere seemed to have flown back.Epigastric pain developed soon after treatment.The patient also had strong queasiness and vomiting.The symptoms exacerbated and bth pancreatic amylase and lipase levels increased.Then the symptoms improved after futhan (nafamostat mesilate) administration and fasting.On (b)(6), patient started oral intake.On (b)(6) patient was discharged from the hospital.
 
Manufacturer Narrative
Nothing is expected to be returned for evaluation.Since the lot number was not provided, the device history record and complaint database could not be reviewed for similar issues.The instructions for use provide a warning to pay careful attention for signs of mis-targeted embolization.During injection, it is required to carefully monitor patient vital signs to include sao2 (e.G.Hypoxia, en changes).And consider terminating the procedure, investigating for possible shunting, or increasing microsphere size if any signs of mis-targeting occur or patient symptoms develop.Merit is unable to determine a root cause.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
EMBOSPHERE MICROSPHERES
Type of Device
AGENTS, EMBOLIC, TREAT. UTER. FIBRO
Manufacturer (Section D)
BIOSPHERE MEDICAL, S.A.
roissy en france
FR 
Manufacturer Contact
alix fonlladosa
parc de nations, paris nord 2
383, rue de la belle etoie
roissy en france 
FR  
48172529
MDR Report Key4336126
MDR Text Key15344063
Report Number9615728-2014-00003
Device Sequence Number1
Product Code NAJ
Combination Product (y/n)N
Reporter Country CodeJA
PMA/PMN Number
K021397
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Distributor
Reporter Occupation Not Applicable
Type of Report Initial
Report Date 11/04/2014
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/26/2014
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Catalogue NumberS220GH
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Date Manufacturer Received11/04/2014
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Hospitalization; Other;
Patient Age64 YR
Patient Weight53
-
-